Nurix Therapeutics to Engage in Investor Conferences
Nurix Therapeutics, Inc. (NASDAQ: NRIX), a pioneering clinical-stage biopharmaceutical company, focuses on innovative solutions in targeted protein degradation medicines. The company has a solid reputation in developing groundbreaking treatments aimed at addressing cancer and inflammatory diseases. Recently, Nurix announced that its President and CEO, Arthur T. Sands, M.D., Ph.D., will be participating in vital investor conferences this November.
Details About the Conferences
The upcoming conferences feature important fireside chats that will highlight the company’s advancements and future directions. Key events include:
Stifel 2025 Healthcare Conference
This conference is scheduled for Thursday, November 13, 2025, from 9:20 to 9:50 a.m. ET. It provides an excellent opportunity for Nurix to share insights and updates with investors.
Jefferies Global Healthcare Conference
The Jefferies conference will take place on Wednesday, November 19, 2025, from 11:00 to 11:25 a.m. GMT, another platform for Nurix to showcase its innovative drug discovery efforts.
Webcast and Access Information
Investors can tune in to the live webcasts of these fireside chats through the Investors section of the Nurix website. Additionally, the webcasts will be archived and accessible for 30 days following the events, ensuring that everyone has the chance to catch up on the discussions.
About Nurix Therapeutics, Inc.
Nurix is committed to advancing the field of targeted protein degradation medicines, which offer promising new avenues for treating various diseases. Its innovative pipeline includes degrader therapies targeting Bruton's tyrosine kinase (BTK) and inhibitors of Casitas B-lineage lymphoma proto-oncogene B (CBL-B). The company is also progressing several noteworthy programs in its preclinical pipeline, including additional innovative degrader antibody conjugates (DACs).
Moreover, Nurix's partnered approach in drug discovery involves collaborations with renowned companies like Sanofi, Gilead, and Pfizer, allowing exploration of co-development and commercialization opportunities for its promising drug candidates. They leverage an AI-integrated discovery engine that enhances their capability to innovate across numerous protein classes.
Advancements in Biopharmaceuticals
Nurix strives to put patient care first by putting degrader technologies to the forefront, aiming to revolutionize treatment methodologies. This vision embodies a commitment to breaking new ground in therapeutic approaches that tackle diseases more effectively.
Contact Information
For more information, Nurix Therapeutics can be reached via the following contacts:
Investor Inquiries
Kris Fortner,
Nurix Therapeutics, Inc.
Email: kfortner@nurixtx.com
Media Relations
Aljanae Reynolds,
Wheelhouse Life Science Advisors
Email: areynolds@wheelhouselsa.com
Frequently Asked Questions
What is Nurix Therapeutics known for?
Nurix Therapeutics is known for its innovative research in targeted protein degradation and the development of novel therapies for cancer and inflammatory diseases.
When are the upcoming investor conferences?
The investor conferences are scheduled for November 13 and November 19, 2025.
How can I access the live webcasts of the events?
The live webcasts can be accessed via the Investors section on the Nurix website.
What collaborations does Nurix have?
Nurix has notable collaborations with Sanofi, Gilead, and Pfizer, focusing on joint drug development and commercialization efforts.
What role does AI play in Nurix's research?
AI significantly enhances Nurix's drug discovery capabilities, enabling them to innovate across various protein classes efficiently.